Entasis Therapeutics Holdings Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|
| Revenue | — | — | $7.0M | $5.0M | — |
| Operating income | −$52.3M | −$54.2M | −$46.9M | −$38.2M | −$31.3M |
| Net income | −$47.1M | −$50.5M | −$43.9M | −$33.0M | −$29.9M |
| Total assets | $40.9M | $61.6M | $51.0M | $89.3M | $58.8M |
| Total liabilities | $9.7M | $9.3M | $8.9M | $6.4M | $9.9M |
| Equity | $31.2M | $52.3M | $42.2M | $82.9M | −$55.8M |
| EPS (diluted) | $-1.09 | $-2.10 | — | — | — |
| Shares out. | 37.3M | 13.3M | 13.1M | 13.1M | 12,639 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2021- Operating margin
- —
- Net margin
- —
- Return on equity
- −151.0%
- Return on assets
- −115.2%
- Return on capital (ROCE)
- −167.6%
- Liabilities / assets
- 23.7%
- Debt / equity
- 0.31×
- Book value / share
- $0.84
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2021- Altman Z″ (distress)
- -18.84distress
- Accruals / assets
- −10.2%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Director / officer change · Amended charter or bylawsJul 11, 2022
- Entered a material agreement · Other material eventMay 23, 2022
- Results of operationsApr 27, 2022
- Results of operationsMar 3, 2022
- Director / officer changeFeb 25, 2022
- Entered a material agreement · New financial obligation · Unregistered equity sale · Modified shareholder rightsFeb 18, 2022
- Director / officer changeJan 14, 2022
- Director / officer changeNov 12, 2021
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.